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  The receptor activator of NF-κB ligand (RANKL) signal is an activator of tumor necrosis factor 
receptor-associated factor 6 (TRAF6), which leads to the activation of NF-κB and other signal 
transduction pathways essential for osteoclastogenesis, such as Ca
2＋ signaling. However, the intra-
cellular levels of inositol 1,4,5-trisphosphate (IP3) and IP3-mediated cellular function of RANKL during 
osteoclastogenesis are not known. In the present study, we determined the levels of IP3 and evaluated 
IP3-mediated osteoclast differentiation and osteoclast activity by RANKL treatment of mouse leukemic 
macrophage cells (RAW 264.7) and mouse bone marrow-derived monocyte/macrophage precursor cells 
(BMMs). During osteoclastogenesis, the expression levels of Ca
2＋ signaling proteins such as IP3 
receptors (IP3Rs), plasma membrane Ca
2＋ ATPase, and sarco/endoplasmic reticulum Ca
2＋ ATPase 
type2 did not change by RANKL treatment for up to 6 days in both cell types. At 24 h after RANKL 
treatment, a higher steady-state level of IP3 was observed in RAW264.7 cells transfected with green 
fluorescent protein (GFP)-tagged pleckstrin homology (PH) domains of phospholipase C (PLC) δ, a 
probe specifically detecting intracellular IP3 levels. In BMMs, the inhibition of PLC with U73122 [a 
specific inhibitor of phospholipase C (PLC)] and of IP3Rs with 2-aminoethoxydiphenyl borate (2APB; 
a non-specific inhibitor of IP3Rs) inhibited the generation of RANKL-induced multinucleated cells and 
decreased the bone-resorption rate in dentin slice, respectively. These results suggest that intracellular 
IP3 levels and the IP3-mediated signaling pathway play an important role in RANKL-induced osteo-
clastogenesis.
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INTRODUCTION
  Bone is a connective tissue that constructs the skeleton 
and is composed of the intracellular matrix proteoglycans, 
osteoblasts, osteoclasts, and osteocytes. It is a dynamic tis-
sue that is constantly renewed by bone remodeling. Bone 
remodeling is an active process and is regulated by the ac-
tivity of bone-forming osteoblasts and bone-resorbing osteo-
clasts [1,2]. In fact, an imbalance in bone remodeling can 
cause pathological conditions such as rheumatoid arthritis, 
osteoporosis, and osteopetrosis. 
  Cells grow and differentiate through cell-to-cell inter-
actions, and extracellular signals lead to specific cell re-
actions through signal transduction. Cell-to-cell signaling 
of mesenchymal cells, including osteoblasts, induces the dif-
ferentiation of osteoclast precursor cells into mature osteo-
clasts [3,4]. Receptor activator of nuclear factor kappa B 
(NF-κB) ligand (RANKL) is expressed on the surfaces of 
osteoclasts, and an essential factor for osteoclast differen-
tiation. RANKL, a member of the tumor necrosis factor 
(TNF) family, is expressed in the bone, bone marrow, and 
lymphoid tissue during osteoclastogenesis. RANKL binds to 
RANK and transmits a differentiation signal [5]. It is 
known that RANKL stimulation initially activates tumor 
necrosis factor receptor-associated factor 6 (TRAF6), and 
then sequentially activates NF-κB, c-fos, JNK, ERK, and 
PI3K in osteoclast precursor cells [6,7]. Recent studies of 
osteoclastogenesis have focused on TRAF6, JNK, and NF-κB 
signaling pathways triggered by the binding of RANKL to 
RANK on osteoclast precursors. During osteoclastogenesis, 
auto-amplification of NFATc1 induces osteoclast-specific 
genes including AP-1, tartrate-resistant acid phosphatase 
(TRAP), calcitonin receptor, and cathepsin K [6]. Recently, 
Ca
2＋ signaling has been recognized as an essential pathway 
in the differentiation of osteoclasts. In particular, a pre-32 A Son, et al
vious study has shown that treatment with a Ca
2＋ chelator 
inhibits osteoclastogenesis in osteoclast precursor cells [8], 
suggesting that Ca
2＋ signaling is important in osteoclasto-
genesis. 
  Hormone and neurotransmitter-induced increases in in-
tracellular Ca
2＋ concentration ([Ca
2＋]i) regulate gene ex-
pression, growth, differentiation, muscle contraction, mem-
ory, and learning [9]. Particularly, in osteoclast differ-
entiation, Ca
2＋ was reported to play an important role by 
sequentially activating calcineurin and NFATc1 [5,8,10]. In 
this study, Ca
2＋ signals were shown to exist in a unique 
form, such as Ca
2＋ oscillations, which are a recurring phe-
nomena of increases and decreases in [Ca
2＋]i. Generally, 
in non-excitable cells, the increase in [Ca
2＋]i occurs through 
the activation of Ca
2＋ channels or Ca
2＋ release from the 
ER into the cytoplasm, and is then followed by activation 
of the sarco/endoplasmic reticulum Ca
2＋ ATPase (SERCA) 
and the plasma membrane Ca
2＋ ATPase (PMCA) that re-
move Ca
2＋ from the cytosol [11,12]. In most cells, extracel-
lular signals such as hormones and neurotransmitters stim-
ulate phospholipase C (PLC) and then hydrolyze a plasma 
membrane lipid phosphatidyl-inositol bisphosphate (PIP2) 
to generate inositol 1,4,5-trisphosphate (IP3) in the cytosol. 
Increased levels of IP3 promote Ca
2＋ release into the cytosol 
by changing Ca
2＋ permeability of the IP3Rs in the ER, 
which is the intracellular Ca
2＋ store. Ca
2＋ release from the 
ER can change the conductance of Ca
2＋ release-activated 
Ca
2＋ channels. It induces Ca
2＋ influx from an environment 
of high concentration of extracellular Ca
2＋ [12]. An induced 
increase in [Ca
2＋]i is removed by the Ca
2＋ pump. 
Nevertheless, there are no reports on the intracellular lev-
els of IP3 in osteoclast differentiation. In the present study, 
we assessed the levels of IP3 and the associated IP3-induced 
osteoclast differentiation and activity during RANKL-medi-
ated osteoclastogenesis in osteoclast precursor cells.
METHODS
Cell cultures and reagents
  The mouse monocyte cell line RAW264.7 (Korean Cell 
Line Bank, South Korea) and primary cultured, bone mar-
row-derived monocyte/macrophage precursor cells (BMMs) 
were respectively cultured in Dulbecco’s modified eagle me-
dium (DMEM, Invitrogen, Carlsbad, CA, USA) and α-mini-
mum essential medium (α-MEM, Invitrogen), supple-
mented with 10% fetal bovine serum (FBS) and 1% anti-
biotics, in a 37
oC incubator (5% CO2). To maintain BMMs, 
α-MEM was supplemented with 50 ng/ml macrophage col-
ony-stimulating factor (M-CSF). RANKL and M-CSF were 
purchased from Koma Biotech, Inc. (Seoul, Korea). U73122, 
U73343 and 2-aminoethoxydiphenyl borate (2-APB) were 
from Sigma-Aldrich (St. Louis, MO, USA). Polyclonal anti-
bodies for IP3R1, IP3R2, and IP3R3 were generous gifts from 
Dr. Akihiko Tanimura (Hokkaido University, Japan), and 
the monoclonal antibody for PMCA (5F10) was purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The 
vector containing the PLC δ-PH-GFP construct was a gen-
erous gift from Dr. Shmuel Muallem (NIH/NIDCR, USA).
Preparation of BMMs
  Four-week-old male mice (Koatec, Pyeongtaek, Korea) 
were sacrificed, and the femur and tibia were separated. 
Bone marrow cells derived from the femur and tibia were 
collected and cultured in α-MEM containing 10% FBS and 
10 ng/ml M-CSF. The next day, non-adherent cells in the 
media were collected and seeded on adequate number of 
plates with 50 ng/ml M-CSF. After 2 days, non-adherent 
cells were washed out with fresh media, and the adherent 
cells were used as BMMs.
Western blot analysis
  Whole cell proteins were prepared in lysis buffer [20 mM 
Tris (pH 7.4), 250 mM NaCl, 2 mM EDTA (pH 8.0), 0.1% 
Triton X-100, 0.01 mg/ml aprotinin, 0.005 mg/ml leupeptin, 
0.4 mM PMSF, and 4 mM NaVO4), and the extracts were 
centrifuged at 1,100×g for 10 min to remove insoluble 
material. Cleared extracts (50∼100μg of protein/well) were 
subjected to 6∼12% SDS-PAGE, and the proteins were 
electrotransferred to a nitrocellulose membrane, blocked 
with 6% skimmed milk, and probed with antibodies against 
IP3R1 (1：1,000), IP3R2 (1：5,000), IP3R3 (1：1,000), 
PMCA (1：5,000), SERCA2b (1：5,000). The blots were 
washed, exposed to horseradish peroxidase-conjugated sec-
ondary antibodies for 1 h, and detected by chemilumine-
scence (ECL, Amersham Pharmacia Biotech, Schenectady, 
NY, USA).
Expression of IP3 Sponge and PLC δ-PH-GFP expres-
sion in RAW264.7 cells
  RAW264.7 cells were transiently transfected with a green 
fluorescent protein (GFP)-tagged high affinity (R441Q) or 
low affinity (K508A) IP3-sequestering sponge [13], or were 
transfected with PLC-δ1-PH-GFP construct provided by 
Dr. Shmuel Muallem (NIH/NIDCR, USA) using Lipofecta-
mine 2000 reagent (invitrogen), according to the manu-
facturer’s instructions. Cells were incubated for 48 h at 
37
oC, in a 5% CO2 atmosphere with saturated humidity to 
allow expression of each protein was confirmed by GFP 
fluorescence. 
Measurements of PLC δ-PH-GFP expression in RAW 
264.7 cells 
  After RANKL treatment, GFP-positive cells were identi-
fied, and the GFP density in PLC δ-PH-GFP cDNA-trans-
fected RAW264.7 cells was measured using a confocal laser 
scanning microscope (Leica, Buffalo, NY, USA) at an ex-
citation wavelength of 488 nm and an emission wavelength 
of 525 nm. 
TRAP stain assay
  BMMs were seeded in 48-well plates at a concentration 
of 1×10
4 cells per well and pretreated with indicated 
compounds. Cells were then stimulated with 50 ng/ml 
sRANKL. After 6 days, a TRAP stain assay was performed 
to confirm the cell differentiation rate. TRAP-positive cells 
were stained using a Leukocyte Acid Phosphate Assay Kit 
(Sigma-Aldrich) by following the manufacturer’s procedure. 
TRAP-positive multinucleated cells (containing ≥3 nuclei) 
were then counted.
Measurement of bone-resorption rate (pit assay)
  BMMs were collected from 4-week-old mice, as described IP3 in RANKL-induced Osteoclastogenesis 33
Fig. 1. Effect of receptor activator of NF-κB ligand (RANKL) on 
the expression of Ca
2＋ signaling proteins. RAW264.7 cells and 
mouse bone marrow derived monocyte/macrophage precursor cells 
(BMMs) were treated with RANKL (50 ng/ml). Levels of three types 
of inositol 1,4,5-trisphosphate receptors (IP3Rs), plasma membrane 
Ca
2＋ ATPase (PMCA), and sarco/endoplasmic reticulum Ca
2＋
ATPase (SERCA) 2b were measured at different time points from 
24 h to 6 days after RANKL treatment. 
previously [14]. Collected BMMs were seeded on 48-well 
bone-slice covered plates, coated with an osteoclast activity 
assay substrate (OAAS
TM; OCT, Cheonan, Korea). BMMs 
in bone-sliced plates were maintained with 50 ng/ml M-CSF 
and sRANKL for 15 days. After 15 days, cells were washed 
out with sodium hypochlorite solution for 1 h at room tem-
perature. The bone slices were imaged, and the pits in the 
bone slices were identified based on pixel area calculations. 
The data were expressed relative to the pit areas in 
RANKL-stimulated BMMs by using the MetaMorph soft-
ware (Molecular Devices).
Statistical analyses
  Data from at least three independent experiments were 
expressed as mean±SD. Statistically significant differences 
between groups were determined using the Student t-test. 
RESULTS
RANKL-induced expression of Ca
2＋ signaling proteins 
  To assess the effect of RANKL stimulation on the ex-
pression levels of Ca
2＋ signaling proteins such as IP3R, 
SERCA, and PMCA, RAW264.7 cells and BMMs were treat-
ed with RANKL for 24 h, 48 h, 72 h, and 6 days. There 
were no differences in the expression levels of these Ca
2＋ 
signaling proteins after RANKL treatment (Fig. 1, n=3).
RANKL-induced [Ca
2＋]i oscillations depend on Ca
2＋ 
release from the IP3-sensitive stores
  Pre vious studie s show that Ca
2＋ oscillations were gen-
erated by RANKL stimulation [15]. To confirm the gen-
eration of RANKL-induced Ca
2＋ oscillations, we treated 
RANKL for 48 h on BMMs. As a results, RANKL-induced 
Ca
2＋ oscillations were observed at 48 h (Fig. 2A, n=3). To 
determine the role of PLC/IP3-dependent pathway in 
RANKL-induced Ca
2＋ oscillations, cells were pretreated 
with 10 μM U73122, a specific blocker of PLC, or its in-
active analog, U73343. U73122 prevented RANKL-induced 
Ca
2＋ oscillations, whereas 10 μM U73343 had no effect 
(Fig. 2B, n=3) and inhibition of IP3R with the IP3R inhibitor 
75 μM 2APB inhibited RANKL-induced Ca
2＋ oscillations 
in BMMs (Fig. 2C, n=3). In addition, we also observed that 
expression of the IP3 sponge completely abrogated RANKL- 
induced Ca
2＋ oscillations although the expression of low af-
finity IP3 sponge did not prevent the RANKL-induced Ca
2＋ 
oscillations (Fig. 2D, n=3).
RANKL-mediated changes in intracellular IP3 levels 
  Because there were no differences in expression levels of 
Ca
2＋ signaling proteins after RANKL treatment (Fig. 1), 
we hypothesized that RANKL-mediated activation of PLC 
induced an increase in intracellular IP3 levels, and then se-
quentially generated Ca
2＋ oscillations. To test our hypoth-
esis, we transfected RAW264.7 cells with the PLC δ-PH- 
GFP domain. The localization of PLC δ-PH-GFP domain 
was confirmed using confocal laser microscopy after 24 h 
of RANKL treatment. In the steady state, the PLC δ PH- 
domain was located in the cell membrane in the absence 
of RANKL treatment; however, after 24 h of RANKL treat-
ment, the PH-domain bound to IP3 and then moved into 
the cytoplasm (Fig. 3, n=3).
Effect of PLC and IP3R on RANKL-mediated osteoc-
last differentiation and osteoclast activity
  Based on our finding that RANKL induced an increase 
in intracellular IP3 levels, we further investigated the role 
of PLC and IP3R activation on RANKL-mediated osteoclast 
differentiation and osteoclast activity using a TRAP stain-
ing assay and pit assay. The blockage 10 μM U73122, and 
75 μM 2APB inhibited the generation of RANKL-induced 
multinucleated cells to 60% and 84.3% of the controls, re-
spectively (Fig. 4A, n=3). In addition, we measured osteo-
clast activity in RAW264.7 cells and BMMs using dentin 
slices following U73122 and 2APB treatment. Pit areas in 
RANKL-induced osteoclastogenesis were decreased to 48.4% 
and 93.6% of the controls, respectively (Fig. 4B, n=3).
DISCUSSION
  Osteoclastogenesis requires costimulatory receptor sig-
naling mediated through adaptor proteins that contain im-
munoreceptor tyrosine-based activation motifs (ITAMs), 
such as the Fc receptor γ (FcR γ) and the 12-kDa DNAX- 
activating protein [5]. The active signal transmitted through 
adaptor proteins then induces Ca
2＋ signaling, which se-
quentially activates NFATc1 and induces osteoclast differ-
entiation [5,10]. In addition, the signal via TRAF6 activates 
transcription factors such as c-fos and NF-κB [4] and the 
Ca
2＋ signal and activation of NFATc1 are transduction sig-
nals occurring after the middle stage of osteoclast differ-
entiation in most cells. It is likely that activation of IP3Rs 
in the ER may induce Ca
2＋ oscillations. Because there was 
no way to directly measure the intracellular concentration 
of IP3, we transfected cells with a PLC δ-PH domain [16]. 
The transfected PLC δ-PH domain binds to PIP2 with high 
specificity and affinity during the resting state. However, 
it is translocated to the cytoplasm and binds to IP3 when 
IP3 accumulates via an external signal because the PLC 
δ-PH domain has a stronger affinity for IP3 than for PIP2 
[16]. We demonstrated that RANKL induces an increase 
in IP3 levels at 24 h after RANKL treatment, after which 34 A Son, et al
Fig. 2. E f f e c t  o f  P L C  a n d  I P 3 inhibition on RANKL-induced [Ca
2＋]i o s c i l l a t i o n s  i n  B M M s .  ( A )  G e n e r a t i o n  o f  C a
2＋ oscillations after 48 
h with RANKL treatment. (B, C) Inhibitory effect of RANKL-induced [Ca
2＋]i oscillations by the PLC inhibitor, U73122 and IP3R inhibitor, 
2APB. (D) Inhibition of RANKL-induced [Ca
2＋]i oscillations by elimination of IP3. 
Fig. 3. Localization of phospholipase 
C (PLC) δ-PH-GFP in RAW264.7 
cells after RANKL stimulation. 
RAW264.7 cells were treated with 
RANKL following their transfection 
with the PLC δ-PH-GFP domain. 
After 24 h with RANKL treatment, 
GFP intensity was measured using 
confocal laser microscopy. The graph 
shows the fluorescence intensity alo-
ng the lines indicated in the images.IP3 in RANKL-induced Osteoclastogenesis 35
Fig. 4. Effects of IP3R inhibitor and PLC inhibitor on RANKL- 
induced multinucleated cell formation and pit formation in BMMs. 
(A) BMMs were seeded in 48-well plates and cultured for 6 days 
with RANKL and M-CSF. RANKL was simultaneously added to 
2-aminoethoxydiphenyl borate (2APB)-, U73122-, and U73343- 
treated cells. Multinucleated cells (MNCs; ≥3 nuclei) in a well are 
presented as MNCs per well. Data from three independent experi-
ments are represented as mean±SD (**p＜0.005 compared with 
RANKL-induced MNC counts). (B) BMMs were seeded on OAAS 
plates, the bottom of which was covered with dentin slices, and 
cultured for 15 days with RANKL and M-CSF. RANKL was 
simultaneously added to 2APB- and U73122-treated cells. Data 
show the relative pit area compared to RANKL-treated BMMs and 
mean±SD obtained from three independent experiments (**p＜
0.005 compared with RANKL-induced pit area).
IP3 binds to the PH-domain and translocates from the mem-
brane to the cytosol. On the other hand, during osteoclasto-
genesis, PLCγ activation is important to generate Ca
2＋ sig-
naling, and this has been confirmed by using the PLC in-
hibitor U73122 [15]. In our study, treatment of cells with 
U73122 inhibited the generation of RANKL-induced Ca
2＋ 
oscillations, multinucleated cells, and reduced the bone-re-
sorption rate. In addition, we observed that treatment with 
2APB, an IP3R inhibitor, inhibited the generation of RANKL- 
induced Ca
2＋ oscillations, multinucleated cells, and reduced 
bone-resorption rate. This result is consistent with a pre-
vious finding that, Ca
2＋ oscillations were not generated and 
in vitro osteoclastogenesis was impaired in IP3R2/3-defi-
cient mice [17]. Therefore, IP3-mediated Ca
2＋ signaling is 
essential for osteoclastogenesis.
  Previous studies showed that Ca
2＋ influx channels located 
on the plasma membrane play an important role in osteo-
clastogenesis [18,19]. Transient receptor potential cation 
channel subfamily V member 4 (TRPV4)-deficient mice led 
to an increase in bone mass; Ca
2＋ oscillations were normal 
in these cells at the early stage of osteoclastogenesis; how-
ever, they gradually disappeared at the later stages. These 
results suggest that Ca
2＋ influx via TRPV4 is necessary 
for Ca
2＋ signaling [19]. TRPV5-deficient mice also showed 
an increase in bone mass, although increased number and 
size of osteoclasts in vivo, suggesting the importance of Ca
2＋ 
influx for resorption activity in mature osteoclasts [18]. 
Therefore, it remains to be determined how Ca
2＋ oscil-
lations and Ca
2＋ channel-mediated Ca
2＋ i n f l u x  r e l a t e  t o  
osteoclastogenesis. 
  In summary, these results suggest that RANKL induces 
increases in intracellular IP3 and IP3 plays an important 
role in osteoclstogenesis. Therefore, manipulation of this 
signaling pathway may provide a target for treatment of 
bone-related disease.
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